ClinicalTrials.gg

Program

TNP-2092

Also written as “TNP-2092 capsules”, “TNP-2092 for injection” and “[14C]-TNP-2092”.

Its studies are mostly in Hyperammonemia · Gram-Positive Bacterial Infections, led by 3 companies.

Furthest: phase 2, since Nov 13, 20239 company-led studies, 1 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TenNor Therapeutics (Suzhou)30 open or runningphase 2since Nov 13, 2023Nov 13, 2023none ahead
TenNor Therapeutics31 open or runningphase 2since Mar 14, 2025Mar 22, 2024Jan 2027phase 2 · NCT06889701
TenNor Therapeutics30 open or runningphase 2since Apr 30, 2019Apr 30, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 30, 2019First study: phase 2 study in Gram-Positive Bacterial InfectionsNew to TenNor TherapeuticsTenNor Therapeutics · NCT03964493 · 120 enrolled · United States
  2. Feb 25, 2020Phase 1 study in Prosthetic Joint InfectionTenNor Therapeutics · NCT04294862 · 13 enrolled · United States
  3. Sep 29, 2021Phase 1 study in HealthyTenNor Therapeutics · NCT05074134 · 6 enrolled · United States
  4. Nov 13, 2023TenNor Therapeutics (Suzhou)'s first study: phase 2 study in HyperammonemiaNew to TenNor Therapeutics (Suzhou)TenNor Therapeutics (Suzhou) · NCT06135675 · 36 enrolled · China
  5. Dec 7, 20232 phase 1 studiesTenNor Therapeutics (Suzhou) · NCT06178718, NCT06190340
  6. Mar 22, 2024TenNor Therapeutics's first study: phase 1 study in Helicobacter Pylori InfectionNew to TenNor TherapeuticsTenNor Therapeutics · NCT06337604 · 20 enrolled · China
  7. Apr 27, 2024Phase 1 study in Acute Bacterial Skin and Skin Structure Infection (ABSSSI)TenNor Therapeutics · NCT06394518 · 32 enrolled · China
  8. Mar 14, 2025Phase 2 study in Periprosthetic Joint Infection (PJI)TenNor Therapeutics · NCT06889701 · 33 planned · China

Ahead

  1. Jan 2027Primary completion: phase 2 study in Periprosthetic Joint Infection (PJI)TenNor Therapeutics · NCT06889701

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Bacterial DNA-directed RNA polymerase inhibitor; Bacterial DNA gyrase inhibitor; Topoisomerase IV inhibitor”ChEMBL 37, by rule

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06889701Periprosthetic Joint Infection (PJI) · China2RecruitingTenNor TherapeuticsJan 202733
NCT06394518Acute Bacterial Skin and Skin Structure Infection (ABSSSI) · China1CompletedTenNor TherapeuticsFeb 24, 202332
NCT06337604Helicobacter Pylori Infection · China1CompletedTenNor TherapeuticsNov 23, 201720
NCT06190340Helicobacter Pylori Infection · China1CompletedTenNor Therapeutics (Suzhou)Sep 26, 201740
NCT06178718Hyperammonemia · China1CompletedTenNor Therapeutics (Suzhou)Aug 2, 201658
NCT06135675Hyperammonemia · China2CompletedTenNor Therapeutics (Suzhou)Jun 16, 202136
NCT05074134Healthy · United States1CompletedTenNor TherapeuticsNov 30, 20216
NCT04294862Prosthetic Joint Infection · United States1CompletedTenNor TherapeuticsDec 31, 202113
NCT03964493Gram-Positive Bacterial Infections · United States2CompletedTenNor TherapeuticsSep 28, 2020120

How it is read

Names in the registry

  • “TNP-2092 capsules”, 4 entries
  • “TNP-2092 for injection”, 2 entries
  • “TNP-2092”, 2 entries
  • “[14C]-TNP-2092”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.